Chemomab Director Holds 35k Shares, Signals Confidence as Stock Hovers 28% Below 52‑Week High【News Flash】
Insider confidence signals a potential upside for Chemomab Therapeutics, highlighting strategic pivot, clinical milestones and market sentiment to guide investors.
6 minutes to read
